Am J Clin Pathol. 2020 Nov 25 doi: 10.1093/ajcp/aqaa252
Dieter De Smet, MD,1 Kristof De Smet, MD,2 Pauline Herroelen, MSc,1 Stefaan Gryspeerdt, MD,2 and Geert A Martens, MD, PhD1,3,4
COVID-19 treated by Vitamin D - studies, reports, videos
As of Jan 26 had: 34 trials, 4 trial results, 13 meta-analyses and reviews, 46 observations, 27 recommendations, 42 associations, 84 speculations, 38 videos see also COVID-19 and Vitamin D: Governments. Health problems. Hospitals
Clinical trials are proving that Vitamin D fights COVID-19 in hospitals includes
3 very successful Clinical Trials have been published so far (31 trials underway)
- COVID-19 defeated by calcifediol form of Vitamin D in Spain - pilot RCT Aug 29, 2020
- Trial used a faster-acting form of vitamin D which is only available by prescription
- COVID-19 defeated 3x faster by 420,000 IU Vitamin D nanoemulsion – RCT Nov 12, 2020 - supplier not stated
- Nanoemulsion forms of Vitamin D might be faster acting than Calcifediol (above) if swished in the mouth (gets directly to the blood, is not delayed by gut)
- 20+ Vitamin D emulsion suppliers on Amazon Nutrasal Micro D3 1 teaspoon = 200,000 IU
- but not (yet) available thru pharmacies nor medical suppliers
- 2X fewer COVID-19 deaths observed with 300,000 IU of vitamin D
- - - - - - - - - - - - - - -
- Vitamin D recommended to fight COVID-19 by 2 groups – Dec 7, 2020
- 5.8 X more likely to die of COVID-19 if low vitamin D - Systematic Review Dec 3, 2020
- - - - - - - - - - - -
The study was reviewed in Medscape
"This study shows how severe a problem this is," Teitelbaum told Medscape Medical News. "A 3.7-fold increase in death rate if someone's vitamin D level was below 20 [ng/mL] is staggering. It is arguably one of the most important risk factors to consider."
Vitamin D deficiency was previously correlated with incidence and severity of coronavirus disease 2019 (COVID-19). We investigated the association between serum 25-hydroxyvitamin D (25(OH)D) level on admission and radiologic stage and outcome of COVID-19 pneumonia.
A retrospective observational trial was done on 186 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected individuals hospitalized from March 1, 2020, to April 7, 2020, with combined chest computed tomography (CT) and 25(OH)D measurement on admission. Multivariate regression analysis was performed to study if vitamin D deficiency (25(OH)D <20 ng/mL) correlates with survival independently of confounding comorbidities.
Of the patients with COVID-19, 59% were vitamin D deficient on admission: 47% of females and 67% of males. In particular, male patients with COVID-19 showed progressively lower 25(OH)D with advancing radiologic stage, with deficiency rates increasing from 55% in stage 1 to 74% in stage 3. Vitamin D deficiency on admission was not confounded by age, ethnicity, chronic lung disease, coronary artery disease/hypertension, or diabetes and was associated with mortality (odds ratio [OR], 3.87; 95% confidence interval [CI], 1.30-11.55), independent of age (OR, 1.09; 95% CI, 1.03-1.14), chronic lung disease (OR, 3.61; 95% CI, 1.18-11.09), and extent of lung damage expressed by chest CT severity score (OR, 1.12; 95% CI, 1.01-1.25).
Low 25(OH)D levels on admission are associated with COVID-19 disease stage and mortality.